Company intelligence / Profile preview

The Revel Group

San Francisco, California, United Statestherevelgroup.com ↗

Ownership: Private
Development stage: Other

Overview

Revel Pharmaceuticals is developing first-in-class therapeutic enzymes that target and break down glucosepane crosslinks in collagen, aiming to reverse tissue stiffening associated with aging. Their approach has shown promising preclinical results in animal models, but no human clinical data have been reported yet.

Therapeutic areas: DermatologyEndocrinologyNephrologyRheumatologyCardiovascular
Modalities: EnzymeSmall moleculeBiologic (therapeutic enzyme)
Industry: Biotech

Partnerships

Kizoo Technology Capital (investor/partner)SENS Research Foundation (collaborator/founder support)

Beyond the preview

Go deeper on The Revel Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Revel Group.

Explore the full profile